The Estradiol-Dihydrotestosterone model of prostate cancer

Theoretical Biology and Medical Modelling

Volumn 2, Issue , 2005, Pages

  Friedman, A Edward ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANOLONE; ESTRADIOL; FINASTERIDE; TAMOXIFEN; TESTOSTERONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER MODEL; CELL DEATH; CELL GROWTH; CONTROLLED STUDY; ESTROGEN ACTIVITY; FEMALE; GENE EXPRESSION REGULATION; HORMONE ACTION; HORMONE METABOLISM; MOUSE; NONHUMAN; PROSTATE CANCER; PROTEIN EXPRESSION; TELOMERE; ANIMAL; BIOLOGICAL MODEL; HUMAN; MALE; METABOLISM; PATHOLOGY; PROSTATE TUMOR;

ANIMALS; DIHYDROTESTOSTERONE; ESTRADIOL; FEMALE; HUMANS; MALE; MICE; MODELS, BIOLOGICAL; PROSTATIC NEOPLASMS;

EID: 18044398746     PISSN: 17424682     EISSN: None     Source Type: Journal    
DOI: 10.1186/1742-4682-2-10     Document Type: Article

References (23)

1. Ross RK, Pike MC, Coetzee GA, Reichardt JKV, Mimi CY, Feigelson H, Stanczyk FZ, Kolonel LN, Henderson BE: Androgen metabolism and prostate cancer: establishing a model of genetic susceptibility. Cancer Res 1998, 58:4497-4504.
2. Prehn RT: On the Prevention and Therapy of Prostate Cancer by Androgen Administration. Cancer Res 1999, 59:4161-4164.
3. Gann PH, Hennekens CH, Ma J, Longcope C, Stampfer MJ: Prospective study of the sex hormone levels and risk of prostate cancer. J Nat Cancer Inst 1996, 88:1118-1126.
4. Wang YZ, Hayward SW, Cao M, Young P, Cunha GR, Cardiff RD: Role of estrogen signaling in prostatic hormonal carcinogenesis. J Urol (Suppl) 2001, 165:132-133.
5. Risbridger GP, Bianco JJ, Ellem SJ, McPherson SJ: Oestrogens and prostate cancer. Endocr Relat Cancer 2003, 10:187-191.
6. Nanni S, Narducci M, Della Pietra L, Moretti F, Grasselli A, De Carli P, Sacchi A, Pontecorvi A, Farsetti A: Signaling through estrogen receptors modulates telomerase activity in human prostate cancer. J Clin Invest 2002, 110:219-227.
7. Kim NW: Clinical implications of telomerase in cancer. Eur J Cancer 1997, 33:781-786.
8. Corey E, Quinn JE, Emond MJ, Buhler KR, Brown LG, Vesella RL: Inhibition of Androgen-independent Growth of Prostate Cancer Xenografts by 17β-Estradiol. Clin Cancer Res 2002, 8:1003-1007.
9. Imamov O, Morani A, Shim GJ, Omoto Y, Thulin-Andersson C, Warner M, Gustafsson JÅ: Estrogen receptor β regulates epithelial cellular differentiation in the mouse ventral prostate. PNAS 2004, 101:9375-9380.
10. Kandouz M, Siromachkova M, Jacob D, Chretien Marquet B, Therwath A, Gompel A: Antagonism between estradiol and progestin on Bcl-2 expression in breast-cancer cells. Int J Cancer 1996, 68:120-125.
11. Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, Greene GL: The Structural Basis of Estrogen Receptor/Coactivator Recognition and the Antagonism of This Interaction by Tamoxifen. Cell 1998, 95:927-937.
12. Hatzoglou A, Kampa M, Kogia C, Charalampopoulos I, Theodoropoulos PA, Anezinis P, Dambaki C, Papakonstanti EA, Stathopoulos EN, Stournaras C, Gravanis A, Castanas E: Membrane androgen receptor activation induces apoptotic regression of human prostate cancer cells in vitro and in vivo. J Clin Endocrinol Metab 2005, 90:893-903.
13. Xiao W, Zhang Q, Jiang F, Pins M, Kozlowski JM, Wang Z: Suppression of Prostate Tumor Growth by U19, a Novel Testosterone-regulated Apoptosis Inducer. Cancer Res 2003, 63:4698-4704.
14. Oram S, Jiang F, Cai X, Haleem R, Dincer Z, Wang Z: Identification and Characterization of an Androgen-Responsive Gene Encoding an Aci-Reductone Dioxygenase-Like Protein in the Rat Prostate. Endocrinology 2004, 145:1933-1942.
15. Bologna M, Muzi P, Festuccia C, Vicentini C: Finasteride dosedependently reduces the proliferation rate of the LnCap human prostatic cancer cell line in vitro. Urology 1995, 45:282-290.
16. Brendler H, Chase WE, Scott WW: Prostatic cancer: further investigation of hormonal relationships. Arch Surg 1950, 61:433-440.
17. Prout GR, Brewer WR: Response of men with advanced prostatic carcinoma to exogenous administration of testosterone. Cancer 1967, 20:1871-1878.
18. Gunawardena K, Murray DK, Meikle AW: Testosterone is a potential augmentor of antioxidant-induced apoptosis in human prostate cancer cells. Cancer Detect Prev 2002, 26:105-113.
19. Bruckheimer EM, Spurgers K, Weigel NL, Logothetis C, McDonnell TJ: Regulation of Bcl-2 expression by dihydrotestosterone in hormone sensitive LNCaP-FGC prostate cancer cells. J Urol 2003, 169:1553-1557.
20. Matthews J, Gustafsson JÅ: Estrogen Signaling: A Subtle Balance Between ERα and ERβ. Molecular Interventions 2003, 3:281-292.
21. Ockrim JL, Lalani E-N, Laniado ME, Carter SStC, Abel PD: Transdermal Estradiol Therapy for Advanced Prostate Cancer-Forward to the Past? J Urol 2003, 169:1735-1737.
22. Zhu N, Wang Z: Calreticulin Expression Is Associated with Androgen Regulation of the Sensitivity to Calcium Ionphore-induced Apoptosis in LNCaP Prostate Cancer Cells. Cancer Res 1999, 59:1896-1902.
23. Sun J, Huang YR, Harrington WR, Shubin S, Katzenellenbogen JA, Katzenellenbogen BS: Antagonists Selective for Estrogen Receptor α. Endocrinology 2002, 143:941-947.